Pharma Patent Cliff is drug companies optimize for high-margin chronic conditions, not cures. It sits in the Incentives dimension (INC) of the Human Behavior Taxonomy™ as element HBT-INC-0202, within the Healthcare Perverse Pattern family. The core principle: drug companies optimize for high-margin chronic conditions, not cures. In incentive terms, it matters because it changes the payoff people perceive before they choose — which means it can be designed for, or exploited.
Scientific Definition
Drug companies optimize for high-margin chronic conditions, not cures.
Plain-English Definition
Drug companies optimize for high-margin chronic conditions, not cures.
Feynman Explanation
A cure is a one-time revenue event. A treatment is an annuity.
Core Principle
Drug companies optimize for high-margin chronic conditions, not cures.
Mechanisms
Pending editorial review.
Drug companies optimize for high-margin chronic conditions, not cures.
Pending editorial review.
Pending editorial review.
Innovation portfolios shaped by IP economics, not by patient need.
Pending editorial review.
Pending editorial review.
Inputs (Triggers)
Pending editorial review.
Outputs (Behaviors)
Pending editorial review.
Behavioral Signature
A cure is a one-time revenue event. A treatment is an annuity.
Examples
- More R&D on chronic management than on disease elimination.
- Innovation portfolios shaped by IP economics, not by patient need.
Pending editorial review.
Original analysis from The Incentives Lab — how this element behaves inside real payoff structures.
Why this element matters to incentive design
Executives usually notice this element only after it has cost something. By then it looks like a one-off. It is not. The mechanism underneath it is straightforward: drug companies optimize for high-margin chronic conditions, not cures. You can recognize it in the field by its signature: a cure is a one-time revenue event. A treatment is an annuity. Every element in the Incentives dimension changes the perceived payoff of an action before the action happens, which is exactly where incentive design has leverage.
How it gets exploited
Left undesigned, innovation portfolios shaped by IP economics, not by patient need. It is amplified whenever innovation portfolios shaped by IP economics, not by patient need. Inside organizations that shows up as innovation portfolios shaped by IP economics, not by patient need. The pattern is the same one Goodhart's Law describes: the measurable proxy attracts the effort, and the purpose behind it quietly loses funding.
How the Lab designs around it
The redesign move is to public-private hybrid funding for under-incentivized disease classes. Measure the behavior, not the sentiment. A survey will tell you how people feel about this; only observed action tells you whether it changed.
Famous Experiments
Pending editorial review.
Design Principles
- Public-private hybrid funding for under-incentivized disease classes.
Measurement Approaches
Pending editorial review.
Evidence
Pending editorial review.
Pending editorial review.
The Perverse Incentive Lens™
How this behavior is exploited — and how to redesign around it.
- Public-private hybrid funding for under-incentivized disease classes.
Pending editorial review.
Pending editorial review.
Interactive Mini Network
Click any neighbor to re-center the graph and follow the threads of connection.
Knowledge Graph Neighbors
Auto-linked to the rest of the Human Behavior Taxonomy by family, domain, dimension, and shared keywords.
Productivity targets compress visits, raising misdiagnosis and burnout.
A federal mandate intended to lower drug costs for the poor became a profit engine for hospitals and contract pharmacies.
Liability exposure pushes clinicians to order tests for legal protection rather than clinical need.
Federal reimbursement rules incentivize cycling seniors through hospitalizations to upgrade billing categories.
Paying providers per procedure rewards more procedures, not better outcomes.
Systems paid per filled bed have weak incentives to invest in prevention or community health.
Opaque billing rules create lucrative work for administrators and revenue-cycle firms instead of care.
Insurers profit when claims are denied, delayed, or abandoned.
Hospital group-purchasing and opaque contracting inflate device costs far above marginal cost.
Sales bonuses and prescriber relationships fueled mass over-prescription and an addiction crisis.
Federal incentives meant for neglected diseases get used to privatize widely available medicines.
Specialists earn more for procedures than primary care for prevention.
Where Pharma Patent Cliff is cited in the corpus
Essays, field guides, and diagnostics from The Incentives Lab that apply this element.
- Field guideIncentives: definition, types, examples
The parent field guide for this element.
- ReferenceThe laws of incentives
Goodhart, Campbell, and the Cobra Effect.
- CourseIncentives 101
The free ten-part primer on reading a payoff structure.
- ReferenceThe incentive glossary
Definitions for every mental model, bias, and fallacy in the corpus.
- ReferenceThe Periodic Table of Human Behavior
The full 1,267-element map this page belongs to.
Questions about Pharma Patent Cliff
- What is Pharma Patent Cliff?
- Pharma Patent Cliff is drug companies optimize for high-margin chronic conditions, not cures. It sits in the Incentives dimension (INC) of the Human Behavior Taxonomy™ as element HBT-INC-0202, within the Healthcare Perverse Pattern family. The core principle: drug companies optimize for high-margin chronic conditions, not cures. In incentive terms, it matters because it changes the payoff people perceive before they choose — which means it can be designed for, or exploited.
- What is an example of Pharma Patent Cliff?
- Innovation portfolios shaped by IP economics, not by patient need. The Incentives Lab catalogs everyday, organizational, and historical instances of this element on its Human Behavior Taxonomy™ page (HBT-INC-0202).
- How is Pharma Patent Cliff exploited?
- Innovation portfolios shaped by IP economics, not by patient need.
- How do you design around Pharma Patent Cliff?
- Public-private hybrid funding for under-incentivized disease classes.
- Which behavioral dimension does Pharma Patent Cliff belong to?
- Pharma Patent Cliff is classified in the Incentives dimension (INC) of the Human Behavior Taxonomy™, family "Healthcare Perverse Pattern", class "Perverse Incentive". Its permanent identifier is HBT-INC-0202 and its evidence grade is C.